NVS

Novartis

NYSE

Add Alert

NVS

Novartis

NYSE

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older Newer

1jas

08/25/23 9:47 PM

Post #420

have you seen yesterday that enzolytics pharm announced that they now have a CURE for hiv/aids called clone3.?

ernie44

08/01/23 2:00 PM

Post #419

its a home run ---or is it just the runs

https://apis.mail.yahoo.com/ws/v3/mailboxes/@.id==VjN-cV7LhC8rx0EcG5-z9RhWgRsQvGZwTs2qwUxoYR9UStj84lOVi7ZIeMO8HFiplsA65ZbE_cF9gB9A2TSm5APqCg/messages/@.id==AA43g3BH-2gCZMlFEQgiCNhLPmU/content/parts/@.id==2/thumbnail?appid=YMailNorrin&downloadWhenThumbnailFails=true&pid=2

Bearish

awesomed007 Free

07/17/23 7:56 PM

Post #418

https://www.prnewswire.com/news-releases/dtx-pharma-announces-acquisition-by-novartis-301877974.html. I have cmt. Getting closer to 1st fda approved treatment, hopeful!!!

Bullish

subslover

05/25/22 9:21 AM

Post #417

Former Head of Novartis Respiratory and Allergy Medicine to Advise Clinical Stage Stem Cell Company on COVID-19 and COPD Programs
https://www.otcmarkets.com/stock/TSOI/news/story?e&id=2224788

FACT-MASTER Free

05/04/22 6:57 PM

Post #416

https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only-kisqali-offers-more-life-first-line-setting-postmenopausal-hrher2-advanced-breast-cancer-patients

FACT-MASTER Free

05/04/22 6:56 PM

Post #415

https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma

FACT-MASTER Free

04/13/22 1:11 PM

Post #414

Re: #413: @DewDiligence - FDA approves NVS’ Pluvicto*, a radioligand for CRPC:

Novartis also has a collaboration agreement with TScan Therapeutics for development of TCR-T cancer technology, one of the latest and promising therapeutics that could accompany CAR-T.

https://ir.tscan.com/news-releases/news-release-details/tscan-announces-collaboration-novartis-discovery-and-development

TScan entering clinical Phase 1 in 1H 2022.

DewDiligence PremiumMember

03/23/22 4:47 PM

Post #413

FDA approves NVS’ Pluvicto*, a radioligand for CRPC:

https://www.globenewswire.com/news-release/2022/03/23/2408996/0/en/Novartis-PluvictoTM-approved-by-FDA-as-first-targeted-radioligand-therapy-for-treatment-of-progressive-PSMA-positive-metastatic-castration-resistant-prostate-cancer.html

NVS obtained this agent from the ECYT buyout in 2018 (#msg-144295734).

*f/k/a 177Lu-PSMA-617.

DewDiligence PremiumMember

12/22/21 6:05 PM

Post #412

Re: #406: @DewDiligence - CHMP approves NVS’ Leqvio (inclisiran) for hypercholesterolemia or

FDA approves NVS’ Leqvio—(inclisiran)—for lowering LDL-C:

https://www.prnewswire.com/news-releases/fda-approves-novartis-leqvio-inclisiran-first-in-class-sirna-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year-301450125.html

NVS initially received a CRL from the FDA in late 2020 due to the FDA’s inability to conduct an inspection of the Leqvio’s manufacturing site in Italy (#msg-160327185).

Leqvio is a siRNA dosed semiannually (except for the 3-month interval between the first two doses). NVS picked up this drug when it acquired MDCO in Nov 2019 (#msg-152458295).

ALNY, which will get a 10-20% royalty on global sales, discovered Inclisiran and out-licensed it to MDCO in 2013 (#msg-84151150); with the benefit of hindsight we can say that MDCO clearly got the better of ALNY in this deal.

Leqvio was approved in the EI in late 2020 (https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-leqvio-inclisiran-first-class-sirna-lower-cholesterol-two-doses-year ).

DewDiligence PremiumMember

12/16/21 5:56 PM

Post #411

NVS plans $15B share buybacks through 2023—exhausting ~70% of the proceeds from the recent sale of Roche shares:

https://finance.yahoo.com/news/novartis-initiates-usd-15-billion-060000184.html

This might be one reason XBI was down today.

ht1

05/26/21 2:01 PM

Post #410

Novartis should invest in mRNA medicine and pair up with companies like Regen Biopharma to speed up this process. Perhaps an outright purchase of this start up company. This will ensure competing with likes of Pfizer and Moderna.

DewDiligence PremiumMember

12/16/20 8:35 AM

Post #409

FDA_advisory_panel_endorses Entresto for_heart_failure_in_12-1_vote:

https://www.prnewswire.com/news-releases/novartis-announces-positive-fda-advisory-committee-recommendation-for-use-of-entresto-to-treat-patients-with-hfpef-301193607.html

dshade

12/08/20 11:44 AM

Post #408

good news today - Novartis Says Asciminib Showed Superior MMR Rate to Bosulif in Leukemia Trial
December 08 2020 - 11:00AM
Dow Jones News

By Michael Dabaie

Novartis AG said asciminib showed superior major molecular response rate to Bosulif in a chronic myeloid leukemia trial.

The company said results from a Phase III study demonstrate that at 24 weeks, asciminib nearly doubled the major molecular response rate compared with Bosulif in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor therapies.

The data were presented at a late-breaking abstracts session during the 62nd American Society of Hematology Annual Meeting & Exposition, Novartis said.

In the trial, 233 patients were randomized to receive asciminib 40 mg twice daily or Bosulif 500 mg once a day.

Novartis said the U.S. Food and Drug Administration granted Fast Track designation for asciminib. The company said it plans submission to U.S. and EU health authorities in the first half of 2021.

dshade

12/08/20 11:42 AM

Post #407

good news today

DewDiligence PremiumMember

10/16/20 9:38 AM

Post #406

CHMP approves NVS’ Leqvio (inclisiran) for hypercholesterolemia or mixed dyslipidemia:

https://www.globenewswire.com/news-release/2020/10/16/2109800/0/en/Novartis-receives-positive-CHMP-opinion-for-Leqvio-inclisiran-a-potential-first-in-class-siRNA-for-the-treatment-of-high-cholesterol.html

Rubber-stamping by the European Commission will follow in 2-3 months.

DewDiligence PremiumMember

08/20/20 3:09 PM

Post #404

Re: #403: @DewDiligence - Ofatumumab PFUFA delayed 3mo—>Sep 2020 for MS indication:

NVS/GMAB—FDA approves Kesimpta—(subcutaneous ofatumumab)—for MS:

https://finance.yahoo.com/news/u-fda-approves-kesimpta-ofatumumab-173300452.html
https://t.co/9AOLIf7Qln?amp=1

NVS acquired the commercial rights to ofatumumab from GSK, and NVS will pay GSK a tiered royalty up to 12% on worldwide sales of Kesimpta (#msg-116391951).

Ofatumumab, administered via IV, was FDA-approved for CLL under the brand name, Arzerra in 2009 (#msg-42935958).

DewDiligence PremiumMember

06/02/20 4:35 PM

Post #403

Ofatumumab PFUFA delayed 3mo—>Sep 2020 for MS indication:

https://www.globenewswire.com/news-release/2020/06/02/2042559/0/en/Novartis-provides-update-on-FDA-review-of-ofatumumab-a-self-administered-targeted-B-cell-therapy-for-patients-with-relapsing-multiple-sclerosis.html

The PR does not cite a reason for the delay.

NVS acquired Ofatumumab’s commercial rights in MS from GSK in a 2015 transaction involving a $500M up-front payment by NVS (#msg-116391951).

fung_derf

05/19/20 9:57 AM

Post #402

What am I missing here? Why is no one talking about Novartis for their hydroxychloroquine?

DewDiligence PremiumMember

04/09/20 12:22 PM

Post #401

NVS concedes Beovu has new safety issue:

https://www.brolucizumab.info/

Novartis has now completed its review of these post-marketing safety case reports… Based on internal and SRC assessment, it was concluded that there is a confirmed safety signal of rare adverse events of “retinal vasculitis and/or retinal vascular occlusion with or without presence of intraocular inflammation that may result in severe vision loss.”

Based on this review, Novartis has initiated a safety information update to Beovu prescribing information worldwide. Currently approved prescribing information includes intraocular inflammations, visual acuity decrease (including blindness) and retinal artery occlusion as separate terms. We will work with regulatory authorities to finalize the prescribing information update.

In addition, we are working with our data monitoring committees and informing investigators of ongoing clinical trials. Novartis-sponsored studies will be amended so that protocols, Informed Consent Forms and Investigator Brochures reflect this new safety information. Investigators are also being informed to re-consent patients.

Maddog 112 Free

03/23/20 7:03 AM

Post #400

Re: #399: @DewDiligence - It won't have any effect at all on

Ok thank you

DewDiligence PremiumMember

03/22/20 10:26 PM

Post #399

Re: #398: @Maddog 112 - How much will this affect the stock price

It won't have any effect at all on the share price. It's a goodwill gesture and it's the right thing to do morally.

Maddog 112 Free

03/22/20 10:13 PM

Post #398

Re: #397: @DewDiligence - Yes—that was announced on Friday: #msg-154462215.

How much will this affect the stock price 160 mil pills at 4$ is a lot of money

DewDiligence PremiumMember

03/22/20 10:09 PM

Post #397

Re: #396: @Maddog 112 - Is it true NVS to supply 160 mil

Yes—that was announced on Friday: #msg-154462215.

Maddog 112 Free

03/22/20 9:43 PM

Post #396

Re: #395: @DewDiligence - More on the same story (Beovu safety):

Is it true NVS to supply 160 mil chloroquine pills to America to help fight corona virus

DewDiligence PremiumMember

02/25/20 11:04 AM

Post #395

Re: #392: @DewDiligence - The cause is a safety update re Beovu

More on the same story (Beovu safety):

https://endpts.com/novartis-plans-to-wrestle-eylea-market-share-take-a-hit-as-beovu-is-linked-to-safety-concerns/

DewDiligence PremiumMember

02/25/20 7:17 AM

Post #394

Re: #393: @Ecomike - And so this got ignored. :-(

Acceptance of a BLA/NDA application for review doesn’t generally move the needle for a company as large as NVS unless the FDA grants a priority review when investors expected a standard review, which wasn’t the case here.

Ecomike

02/24/20 9:32 PM

Post #393

Re: #392: @DewDiligence - The cause is a safety update re Beovu

And so this got ignored. frown

https://ih.advfn.com/stock-market/NYSE/novartis-NVS/stock-news/81828953/novartis-fda-ema-accept-filings-for-ofatumumab-i?xref=ff_sidebar_quote

DewDiligence PremiumMember

02/24/20 2:40 PM

Post #392

Re: #391: @Ecomike - 5.5% drop on a biotech drug firm like

The cause is a safety update re Beovu (the recently approved drug for AMD):

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153989588

https://www.statnews.com/2020/02/24/safety-concerns-regarding-novartiss-new-eye-drug-boost-regeneron-stock/

Ecomike

02/24/20 2:35 PM

Post #391

Re: #390: @DewDiligence - NVS 12/5/19 R&D Day slides:

5.5% drop on a biotech drug firm like NVS 8 days before the dividend date looks way over done to me with Biotechs in favor and nothing but Good news today and recently on NVS.

Panic selling seems way over done. But then again panics are like that.

You see any bad news at all on NVS I missed?

DewDiligence PremiumMember

12/08/19 6:53 PM

Post #390

Re: #389: @DewDiligence - NVS PR in conjunction with R&D Day investor webcast:

NVS 12/5/19 R&D Day slides:

https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf

DewDiligence PremiumMember

12/05/19 7:37 PM

Post #389

NVS PR in conjunction with R&D Day investor webcast:

https://www.globenewswire.com/news-release/2019/12/05/1956569/0/en/Novartis-expects-to-sustain-long-term-growth-with-a-robust-pipeline-of-25-potential-blockbusters-highlighted-at-R-D-Day.html

elotto777

11/26/19 12:02 PM

Post #388

Re: #387: @DewDiligence - NVS acquires MDCO for $85/sh cash—a 64% premium

These shares are a BUY - Up and Away is how we would describe this company
READ REPORT HERE https://pennystocks.news/biotech-mega-merger-novartis-buys-medicines-co-9-7-billion-deal/

DewDiligence PremiumMember

11/24/19 3:47 PM

Post #387

NVS acquires MDCO for $85/sh cash—a 64% premium to MDCO’s closing price on 11/15/19, the day before serious buyout rumors began circulating:

https://www.globenewswire.com/news-release/2019/11/24/1951667/0/en/Novartis-to-acquire-The-Medicines-Company-for-USD-9-7-bn-adding-inclisiran-a-potentially-transformational-investigational-cholesterol-lowering-therapy-to-address-leading-global-cau.html

https://www.novartis.com/sites/www.novartis.com/files/novartis-mdco-acquisition.pdf (CC slides)

The nominal deal value is $9.7B (on a fully-diluted basis). There is no CVR.

DewDiligence PremiumMember

11/15/19 9:57 AM

Post #386

Re: #365: @DewDiligence - FDA approves NVS’ Mayzent* for MS—including SPMS:

CHMP approves NVS’ Mayzent for SPMS:

https://www.globenewswire.com/news-release/2019/11/15/1947899/0/en/Novartis-receives-positive-CHMP-opinion-for-Mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-SPMS.html

whytestocks Free

11/09/19 8:45 PM

Post #385

News: $NVS ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS

NEW YORK, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business in...

Read the whole news NVS - ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS

DewDiligence PremiumMember

10/08/19 10:18 AM

Post #384

FDA approves NVS’ Beovu—(a/k/a brolucizumab/RTH258) for wet AMD—3mo dosing interval after the loading phase:

https://www.globenewswire.com/news-release/2019/10/08/1926199/0/en/Novartis-receives-FDA-approval-for-Beovu-offering-wet-AMD-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.html

US list price will be $1,850 per vial—inline with main competitor Eylea—according to Vantage (https://www.globenewswire.com/news-release/2019/10/08/1926199/0/en/Novartis-receives-FDA-approval-for-Beovu-offering-wet-AMD-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.html ).

DewDiligence PremiumMember

08/06/19 3:10 PM

Post #383

Re: #382: @Ecomike - Any clue what too the air out this

Here's the cause of today's sell-off:

https://www.wsj.com/articles/fda-says-data-manipulation-occurred-in-trials-of-world-s-priciest-drug-11565116881

Ecomike

08/06/19 3:04 PM

Post #382

Re: #376: @DewDiligence - NVS Investor Day slides:

Any clue what too the air out this one this afternoon?

I see no news yet to justify the swan dive mid day today.

Ecomike

07/12/19 11:54 AM

Post #381

Re: #380: @biopharm - Novartis been researching PS Phosphatidylserine targeting ?

I would love to hear more about that whole story?

biopharm

05/28/19 7:41 AM

Post #380

Re: #337: @biopharm - Novartis been researching PS Phosphatidylserine targeting ?

Novartis been researching PS Phosphatidylserine targeting ?

Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
...
...

Dew, what do you think of the rumors swirling around PS Targeting drugs? Novartis has been swirling all around PS Targeting ever since they brought on Glen Dranoff from Dana Farber ...

Now with Dana Farber Gordon Freeman and Clive Wood enhancing patents that they collaborated on ....patents surrounding PS Targeting are key

PennyStock Alert Free

05/25/19 11:46 AM

Post #379

Green after hours trading

PennyStock Alert Free

05/24/19 2:02 PM

Post #378

Nice news !

whytestocks Free

05/24/19 1:20 PM

Post #377

News: $NVS AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

BASEL, Switzerland , May 24, 2019 /PRNewswire/ -- AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved Zolgensma ® (onasemnogene abeparvovac-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscul...

Got this from https://marketwirenews.com/news-releases/avexis-receives-fda-approval-for-zolgensma-xae-the-first-and-only-gene-therapy-for-pediatric-patients-with-spinal-muscular-atrophy-sma--8242944.html

DewDiligence PremiumMember

05/23/19 11:43 AM

Post #376

Re: #375: @DewDiligence - NVS PR accompanying today’s Investor Day webcast:

NVS Investor Day slides:

https://www.novartis.com/sites/www.novartis.com/files/2019-05-meet-novartis-management-presentation.pdf

DewDiligence PremiumMember

05/23/19 11:30 AM

Post #375

NVS PR accompanying today’s Investor Day webcast:

https://www.globenewswire.com/news-release/2019/05/23/1841255/0/en/Novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-on-strategy-at-Meet-Novartis-Management-investor-event.html

DewDiligence PremiumMember

05/22/19 12:30 PM

Post #374

NVS’ QVM149* scores in phase-2 asthma trial, showing statig-better FEV1 than Advair:

https://www.globenewswire.com/news-release/2019/05/22/1840512/0/en/Novartis-phase-II-data-for-new-inhaled-combination-treatment-QVM149-demonstrates-significant-improvements-over-current-standard-of-care-inhaled-treatment.html

QVM149 is a triple-action LABA/LAMA/ICS drug administered with NVS’ proprietary Breezhaler device. The ICS component of QVM149 is licensed from MRK.

DewDiligence PremiumMember

05/08/19 7:23 PM

Post #373

NVS acquires Xiidra from Takeda for $3.4B up-front and $1.9B in contingent milestones:

https://finance.yahoo.com/news/novartis-buys-takedas-dry-eye-223853867.html

Takeda got Xiidra, which they probably never wanted, via the 2018 acquisition of SHPG (#msg-140610505).

DewDiligence PremiumMember

05/02/19 7:26 PM

Post #372

AMGN and NVS are at war over Aimovig, so they issue separate, essentially identical PRs re Aimovig data presented at AAN:

https://www.prnewswire.com/news-releases/amgen-to-highlight-extensive-long-term-safety-and-efficacy-data-of-aimovig-erenumab-aooe-across-the-spectrum-of-migraine-at-aan-annual-meeting-300843004.html

https://www.globenewswire.com/news-release/2019/05/02/1815773/0/en/Novartis-to-highlight-extensive-long-term-safety-and-efficacy-data-of-Aimovig-across-the-spectrum-of-migraine-at-AAN.html

Silly.

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community